



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/766,317		
		Filing Date	January 27, 2004		
		First Named Inventor	Marinkovich		
		Art Unit	1642		
		Examiner Name	TIDWELL, JUDY LILLE		
Sheet	1	of	5	Attorney Docket Number	Docket 33828/US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MH	A1	U.S. Pat. Pub. No. 2002/0076736	06-20-2002	Findell et al.	
↓	A2	US-4816567	03-28-1989	Cabilly et al.	
	A3	US-6294356	09-25-2001	Jones et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
MH	B1	WO0026342 A	5-11-2000	Northwestern University		
	B2	WO0187239 A	11-22-2001	Fibrogen, Inc. et al.		
	B3	WO 96/04000	02-15-1996	Shah et al.		
	B4	WO 91/04753	04-18-1991	Baer et al.		
	B5	WO 90/10448	09-20-1990	Bischofberger et al.		

NON PATENT LITERATURE DOCUMENTS					T ⁶
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
MH	C1	Ahmed et al. "Chapter 39, Immunity to Viruses" Fundamental Immunology, 4th edition, W. E. Paul, ed., Lippincott-Raven Publishers, 1999, Chapter 39, pp 1295-1334			
	C2	Alama et al. "Antisense Oligonucleotides as Therapeutic Agents" (1997) <i>Pharmacol Res.</i> 36(3):171-178			
	C3	Amano et al., "Bone morphogenetic protein 1 is an extracellular processing enzyme of the Laminin 5Y2 chain" 2000, <i>J. Biol. Chem.</i> , 275: 22728-35			
	C4	Boado et al., "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS" 1998, <i>J. Pharm. Sci.</i> 87 (11): 1308-1315			
	C5	Cassidy et al., "Malanocytes adhere to and synthesize laminin-5 <i>in vitro</i> " <i>Ep. Derm.</i> 1999, 8, 212-221			
	C6	Chan et al. "Laminin-6 and Laminin-5 are recognized by Autoantibodies in a subset of cicatricial pemphigoid" <i>Society for Invs. Derm.</i> , 1997, 848-853			
↓	C7	Chen et al. "NC1 Domain of Type VII Collagen Binds to the β3 chain of laminin 5 via a Unique Subdomain Within the Fibronectin-like repeats" (1999) <i>J. for Invest. Derm.</i> , 177-183			
Examiner Signature		Date Considered			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO (Modified)			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/766,317	
			Filing Date	January 27, 2004	
			First Named Inventor	Marinkovich	
			Art Unit	1642	
			Examiner Name	TIDWELL, JUDY LILLE	
Sheet	2	of	5	Attorney Docket Number	Docket 33828/US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	²
MH	C8	Crooke, S. T., "Advances in understanding the pharmacological properties of antisense oligonucleotides" 1997, <i>Adv. Pharmacol.</i> 40:1-49	
	C9	Dajee et al., "NF- κ B blockade and oncogenic Ras trigger invasive human epidermal neoplasia" <i>Nature</i> vol. 421, 2003, 639-643	
	C10	Diederichsen, U., "Alanyl-PNA homoduplex: A-T Pairing with the N7-Regioisomer of Adenine" 1998, <i>Bioorganic & Med. Chem. Lett.</i> , 8:165-168	
	C11	Fukushima et al., "Integrin $\alpha 3 \beta 1$ -mediated interaction with lamin-5 stimulates adhesion, migration and invasion of malignant glioma cells" 1998, <i>Int. J. Cancer</i> , 76: 63-72	
	C12	Huse et al., "Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda" 1989, <i>Science</i> , 254: 1275-1281	
	C13	Jordan et al., "New Hetero-oligomeric peptide nucleic acids with improved binding properties to complementary DNA" (1997) <i>Bioorg. Med. Chem. Lett.</i> 7: 687-690	
	C14	Jordan et al. "Synthesis of new building blocks for peptide nucleic acids containing monomers with variations in the backbone" (1997) <i>Bioorg. Med. Chem. Lett.</i> 7: 637-627;	
	C15	Kirtschig et al. "Anti-basement membrane autoantibodies in patients with anti-peiligrin cicatricial pemphigoid bind the α subunit of laminin 5", <i>J. Invest. Derm.</i> (1995) 105, 543-548	
	C16	Kumar et al., "Pyrrolidine Nucleic Acids: DNA/PNA Oligomers with 2-hydroxy/aminoethyl-4(thymine-1-yl) pyrrolidine-N-acetic acid" 2001, <i>Organic Letters</i> 3(9): 1269-1272	
	C17	Lavrosky et al., "Therapeutic potential and mechanism of action of oligonucleotides and ribozymes" 1997, <i>Biochem. Mol. Med.</i> 62(1):11-22.	
	C18	Lee et al., "Polyamide Nucleic Acid Targeted to the Primer Binding Site of the HIV-1 RNA Genome Blocks <i>in vitro</i> HIV-1 Reverse Transcription" 1998, <i>Biochemistry</i> 37 (3):900-1010	
	C19	Li et al. "Laminin-10 is crucial for hair morphogenesis" <i>The EMBO Journal</i> , vol. 22, no. 10, pp. 2400-2410	
	C20	Maddox et al., "Elevated serum levels in human pregnancy of a molecule immunochemically similar to eosinophil granule major basic protein" 1983, <i>J Exp Med</i> , 158: 1211	
	C21	Marcus-Sakura "Techniques for using antisense oligodeoxyribonucleotides to study gene expression" (1988) <i>Anal. Biochem.</i> 172:289	
	C22	Marinkovch et al. "Basement Membrane Proteins Kalinin and Nicein are Structurally and Immunologically Identical: <i>Lab. Invest.</i> , 1993, vol. 69, No. 3, pp. 295-299	
V	C23	Marinkovich et al., "The dermal-epidermal junction of human skin contains a novel laminin variant" <i>J. Cell. Biol.</i> vol. 119, no. 3, 1992, 695-703	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO (Modified)				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/766,317
				Filing Date	January 27, 2004
				First Named Inventor	Marinkovich
				Art Unit	1642
				Examiner Name	TIDWELL, JUDY LILLE
Sheet	3	of	5	Attorney Docket Number	Docket 33828/US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	†
MH	C24	Marinkovich M. P. et al, "The Anchoring Filament Protein Kalinin is Synthesized and Secreted as a High Molecular Weight Precursor", <i>Journal of Biological Chemistry</i> , vol. 267, no. 25, 1992, pages 17900-17906	
	C25	McGowan et al. "Laminins and human disease" <i>Microscopy Res. and Tech.</i> 51::262-279 (2000)	
	C26	Meneguzzi et al. "Kalinin is abnormally expressed in epithelial basement membranes of Herliz's junctional epidermolysis bullosa patients" <i>Exp. Derm.</i> 1992, pp. 221-229	
	C27	Meneguzzi et al., "Kalinin is abnormally expressed in epithelial basement membranes of Herliz's junctional epidermolysis bullosa patients", 1992, <i>Exp. Derm.</i> 1, 221-229	
	C28	Miller, "Progress Toward Human Gene Therapy" 1990, <i>Blood</i> , 76: 271	
	C29	Miquel et al., "Establishment and Characterization of cell line LSV5 that retains the altered adhesive properties of human junctional epidermolysis bullosa keratinocytes, <i>Exp. Cell. Res.</i> , 224, 279-290 (1996)	
	C30	Mizushima H. et al., Identification of Integrin-dependent and independent cell adhesion domains in cooh-terminal globular region of alminin-5 alpha3 chain" <i>Cell Growth and Differentiation</i> , The Association, Phil. Pa, US, Vol. 8, no. 9, September 1997 (1997-09), pages 979-987	
	C31	Morris et al., "A new peptide vector for efficient delivery of oligonucleotides into mammalian cells" 1997, <i>Nucl. Acids Res.</i> 25 (14): 2730-2736	
	C32	Nielsen, P. E. and G. Haaime, "Peptide nucleic acid (PNA). a DNA mimic with a pseudopeptide backbone" 1997, <i>Chem. Soc. Rev.</i> 96:73-78	
	C33	O'Toole et al. "Laminin-5 inhibits human keratinocyte migration" <i>Exp. Cell. Res.</i> 233, 330-339 (1997)	
	C34	Orlandi et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction" 1989, <i>Proc. Natl. Acad. Sci.</i> 86: 3833-3837	
	C35	Ortiz-Urda et al. "Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue" <i>J. Clin. Invest.</i> 2003, Vol. 111, No. 2, pps. 251-255	
	C36	Pardridge et al., "Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier <i>in vivo</i> " 1995, <i>Proc. Nat. Acad. Sci.</i> 92 (12):5592-5596	
	C37	Pyke et al., "Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas" 1995, <i>Canc. Res.</i> 55: 4132-4139; Berndt et al., 1997, <i>Invasion and Metastasis</i> , 17: 251-258	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO (Modified)			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/766,317	
			Filing Date	January 27, 2004	
			First Named Inventor	Marinkovich	
			Art Unit	1642	
			Examiner Name	TIDWELL, JUDY LILLE	
Sheet	4	of	5	Attorney Docket Number	Docket 33828/US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
MH	C38	Pyke, et al., "The γ 2 chain of kalinin/Laminin 5 is preferentially expressed in invading malignant cells in human cancers" 1994, <i>Am. J. Pathol.</i> 145(4):782-791		
	C39	Rammensee, H., et al. "SYFPEITHI: database for MHC ligands and peptide motifs": (1999) <i>Immunogenetics</i> , 50:213-219		
	C40	Rossi et al., "Exploring the use of antisense, enzymatic RNA molecules (Ribozymes) as therapeutic agents" 1991, <i>Antisense Res. Dev.</i> 1(3):285-288		
	C41	Rossi, "Therapeutic antisense and ribozymes" 1995, <i>Br. Med. Bull.</i> 51 (1): 217-225		
	C42	Russell et al., " α 6 β 4 integrin regulates keratinocyte chemotaxis through differential GTPase activation and antagonism of α 3 β 1 integrin" 2003, <i>J. Cell Sci.</i> 116 (17):3543-3556		
	C43	Ryan et al. "Cloning of the LamA3 Gene Encoding the alpha3 chain of the adhesive ligand epiligrin" <i>J. Bio. Chem.</i> vol. 269, no. 36, pp. 22779-22787 (1984)		
	C44	Slater et al., "The latex allergen Hev b 5 transcript is widely distributed after subcutaneous injection in BALB/c mice of its DNA vaccine" 1998, <i>J. Allergy Clin. Immunol.</i> 102 (3): 469-475		
	C45	Stoltzfus P. et al., "Lamin-5 Gamma2 Chain Expression Facilitates Detection of Invasive Squamous Cell Carcinoma of the Uterine Cervix, <i>International Journal of Gynecological Pathology</i> , Vol. 23, no. 3, July 2004 (2004-07), pages 215-222		
	C46	Uckert and Walther, "Retrovirus-mediated gene transfer in cancer therapy" 1994, <i>Pharmacol. Ther.</i> , 63(3): 323-347		
	C47	van Hest et al., "Efficient introduction of alkene functionality into proteins in vivo" <i>FEBS Lett</i> 428:(1-2) 68-70 May 22 1998		
	C48	Veitch et al., "Mammalian Tolloid Metalloproteinase, and not matrix metalloprotease 2 or membrane type 1 metalloprotease, processes laminin-5 in keratinocytes and skin" 2003, <i>J. Biol. Chem.</i> , 278: 15661-15668		
	C49	Verhoeyen et al., "Reshaping human antibodies: grafting an antilysozyme activity" 1988, <i>Science</i> , 239: 1534-1536		
	C50	Weinberg et al. "How cancer arises: an explosion of research in uncovering the long-hidden molecular underpinnings of cancer and suggesting new therapies" <i>Scientific American</i> (1996) (September) pps 62-70		
	C51	Winter, G. and C. Milstein, "man-made antibodies" 1991, <i>Nature</i> , 349: 293-299		
	C52	Yi-shan et al. "Self-assembly of Laminin Isoforms" <i>J. Bio. Chem.</i> vol. 272, no. 50, pp 31525-31532 (1997)		

Examiner Signature	/Mark Halvorson/	Date Considered	08/14/2006
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
Error! Bookmark not defined. INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	«ApplicationNo»
				Filing Date	«FilingDate»
				First Named Inventor	«M_1stInventor» «etal»
				Group Art Unit	«ArtUnit»
				Examiner Name	«Examiner»
Sheet	5	of	5	Attorney Docket Number	«FlehrFileNo»/«AttorneyInitials»/«OtherInitials»

4844-8489-7024\13/7/2006 11:56 AM

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
Application Number				10766,317	
Filing Date				January 27, 2004	
First Named Inventor				Marinkovich	
Art Unit				1642	
Examiner Name				TIDWELL, JUDY LILLE	
Attorney Docket Number				Docket 33828/US	
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1				
	A2				
	A3				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
	B1					

NON PATENT LITERATURE DOCUMENTS					⁴
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
MH	C1	Cheng et al. "Self-assembly of laminin isoforms", <i>J. Biol. Sci.</i> , vol. 272, no. 50., pp. 31525-31532 (1997)			
	C2	Marinkovich et al. "LAD-1 is absent in a subset of junctional epidermolysis bullosa patients" <i>The Society for Investig Derm.</i> (1995) vol. 15, pp. 1027-1034			
	C3	Marinkovich et al. "Prenatal diagnosis of herlitz junctional epidermolysis bullosa by amniocentesis" <i>Prenatal Diagnosis</i> (1995) vol. 15, 1027-1034			
	C4	Marinkovich et al. "Basement membrane proteins kalinin and nicein are structurally and immunologically identical" <i>Lab. Invest.</i> (1993), vol. 69, no. 3, 295-			
	C5	Marinkovich et al. "The molecular genetics of basement membrane diseases" <i>Arch. Derm.</i> (1993) vol 129, 1557			
	C6	Marinkovich et al. "The anchoring filament protein kalinin is synthesized and secreted as a high molecular weight precursor" <i>J. Biol. Chem.</i> (1992) Vol. 267, no. 25, pp. 17900-17906			
	C7	Marinkovich et al. "the dermal-epidermal junction of human skin contains a novel laminin variant" (1992) <i>J. Cell Biol.</i> , vol. 119, no. 3, 695-703			

4835-3639-6800\14/14/2006 9:02 AM

Examiner Signature	/Mark Halvorson/	Date Considered	08/14/2006
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2